The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart disease-related death by 20% in a major clinical trial in people with cardiovascular disease
, the first to show a weight loss drug alone can have such protective effects. Novo Nordisk studied Wegovy against placebo in addition to standard of care for prevention of major adverse cardiac events in 17,604 adults with heart disease and obesity or who were overweight, but who didn’t have diabetes. It called the five-year trial “Select.” The finding of a 20% reduction in heart risk is higher than many experts had anticipated.
Wegovy costs $1,349 a month before insurance, and coverage has been difficult for many patients in the US. “For weight loss right now, I would call it poor,” said Dr. Jena Shaw Tronieri, director of Clinical Services at the Center for Weight and Eating Disorders at the Perelman School of Medicine at the University of Pennsylvania, in an interview before the trial results. “We do see a lot of patients struggling to access these medications.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Read more »
Novo Nordisk hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%Shares of Novo Nordisk reached record highs after a study revealed that its Wegovy treatment reduced the risk of heart issues by 20%. The positive results have generated excitement among investors and healthcare professionals.
Read more »
Psychiatrists Prescribe Wegovy for Medication-Induced Weight GainPsychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar disorder.
Read more »
Monthly costs for homebuyers rise nearly 20%The average rate on 30-year fixed mortgage rose to 6.9% this week.
Read more »